Cancer immunotherapy has proven remarkably successful through instigation of systemic antitumor T cell responses. Despite this achievement, further advancements are needed to expand the scope of susceptible cancer types and overcome variation in treatment outcomes between patients. Small-molecule drugs targeting defined pathways and/or cells capable of immune modulation are expected to substantially improve efficacy of cancer immunotherapy. Small-molecule drugs possess unique properties compatible with systemic administration and amenable to both extracellular and intracellular targets. These compounds can modify molecular pathways to overcome immune tolerance and suppression towards effective antitumor responses. Here, we provide an overview of how such effects might be achieved by combining immunotherapy with conventional and/or new small-molecule chemotherapeutics.

中文翻译：

---

小分子在癌症免疫治疗中的机会。

通过激发全身性抗肿瘤T细胞反应，已证明癌症免疫疗法非常成功。尽管取得了这一成就，仍需要进一步的发展来扩大易感癌症类型的范围并克服患者之间治疗结果的差异。靶向靶向确定的途径和/或能够进行免疫调节的细胞的小分子药物有望显着改善癌症免疫疗法的功效。小分子药物具有与全身给药兼容的独特特性，并且适合细胞外和细胞内靶标。这些化合物可以修饰分子途径以克服免疫耐受和抑制有效抗肿瘤反应。这里，